| Identification | Back Directory | [Name]
AZD7507 | [CAS]
1041852-85-0 | [Synonyms]
AZD7507
CS-2850
AZD7507; AZD-7507; AZD 7507;1041852-85-0
4-(2-fluoro-4-methylanilino)-6-[4-(2-hydroxyethyl)piperazin-1-yl]-7-methoxycinnoline-3-carboxamide
3-Cinnolinecarboxamide, 4-[(2-fluoro-4-methylphenyl)amino]-6-[4-(2-hydroxyethyl)-1-piperazinyl]-7-methoxy- | [Molecular Formula]
C23H27FN6O3 | [MOL File]
1041852-85-0.mol | [Molecular Weight]
454.5 |
| Chemical Properties | Back Directory | [Boiling point ]
680.7±65.0 °C(Predicted) | [density ]
1.346±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
Soluble in DMSO | [form ]
Solid | [pka]
14.47±0.30(Predicted) | [color ]
Light yellow to yellow |
| Hazard Information | Back Directory | [Uses]
AZD7507 is a potent and orally active CSF-1R inhibitor, with antitumor activity. | [in vivo]
AZD7507 has good rat oral PK, with in vivo clearance of 7 mL/min/kg and 42% bioavailability. In the canine L-type Ca channel assay, the IC50 is >20 μM[1]. AZD7507 significantly decreases the number of CD68+ macrophages in mice, and also reduces the volume and mass in mice bearing CC-LP-1 and SNU-1079 cells, but not WITT-1 cells[2]. | [storage]
Store at -20°C | [References]
[1] Scott DA, et al. Mitigation of cardiovascular toxicity in a series of CSF-1R inhibitors, and the identification of AZD7507. Bioorg Med Chem Lett. 2013 Aug 15;23(16):4591-6. DOI:10.1016/j.bmcl.2013.06.031
[2] Boulter L, et al. WNT signaling drives cholangiocarcinoma growth and can be pharmacologically inhibited. Send to J Clin Invest. 2015 Mar 2;125(3):1269-85. DOI:10.1172/JCI76452 |
|
|